Channing J. Der

Active 1982–2025

240
Papers
56,713
Citations
127
h-index
234
i10-index

Citations

Citations per year for Channing J. Der1951: 2 citations1979: 1 citations1982: 13 citations1983: 53 citations1984: 60 citations1985: 45 citations1986: 53 citations1987: 45 citations1988: 35 citations1989: 47 citations1990: 111 citations1991: 144 citations1992: 155 citations1993: 141 citations1994: 231 citations1995: 270 citations1996: 263 citations1997: 476 citations1998: 485 citations1999: 672 citations2000: 770 citations2001: 656 citations2002: 658 citations2003: 642 citations2004: 602 citations2005: 584 citations2006: 508 citations2007: 584 citations2008: 471 citations2009: 431 citations2010: 440 citations2011: 448 citations2012: 385 citations2013: 360 citations2014: 405 citations2015: 385 citations2016: 410 citations2017: 408 citations2018: 359 citations2019: 1,221 citations2020: 1,464 citations2021: 1,435 citations2022: 1,135 citations2023: 662 citations2024: 1,132 citations2025: 669 citations2026: 30 citations1952–1978: no citations, so these years are not shown1980–1981: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 7,874 citing papers, 40.1% of this breakdownChina: 1,764 citing papers, 9% of this breakdownUnited Kingdom: 1,134 citing papers, 5.8% of this breakdownGermany: 1,086 citing papers, 5.5% of this breakdownJapan: 847 citing papers, 4.3% of this breakdownCanada: 661 citing papers, 3.4% of this breakdownFrance: 609 citing papers, 3.1% of this breakdownItaly: 589 citing papers, 3% of this breakdownSpain: 423 citing papers, 2.2% of this breakdownNetherlands: 382 citing papers, 1.9% of this breakdownAustralia: 356 citing papers, 1.8% of this breakdownSouth Korea: 336 citing papers, 1.7% of this breakdown
0%40.1%Other 18.2%

Fields

  • Biochemistry, Genetics and Molecular Biology59.3%
  • Medicine29.5%
  • Immunology and Microbiology4.4%
  • Neuroscience2.5%
  • Computer Science0.9%
  • Chemistry0.7%
  • Other2.7%

Topics

  • Protein Kinase Regulation and GTPase Signaling6.7%
  • Melanoma and MAPK Pathways2.8%
  • PI3K/AKT/mTOR signaling in cancer2.5%
  • Cellular Mechanics and Interactions2.4%
  • Cellular transport and secretion2.2%
  • Cancer-related Molecular Pathways2.2%
  • Other81.2%

Coauthors

All papers

Open in search
  1. Drugging the undruggable RAS: Mission Possible?

    Authors: , , , , - Nature Reviews Drug Discovery 2014 cited by 2,003

  2. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anthony N. Milin, Anqi Chen, Tamar Bar Ziv, Dylan Parsons, John E. Knox, Jennifer E. Klomp, Jennifer A. Roth, Matthew G. Rees, Melissa M. Ronan, Antonio Cuevas-Navarro, Feng Hu, Piro Lito, David Santamarı́a, Andrew J. Aguirre, Andrew M. Waters, Channing J. Der, Chiara Ambrogio, Zhengping Wang, Adrian L. Gill, Elena S. Koltun, Jacqueline A.M. Smith, David Wildes, Mallika Singh - Nature 2024 cited by 318

  3. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer

    Authors: , - Cold Spring Harbor Perspectives in Medicine 2017 cited by 866

  4. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

    Authors: , - Oncogene 2007 cited by 2,796

  5. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nina V. Chaika - Nature Medicine 2019 cited by 715

  6. RAS isoforms and mutations in cancer at a glance

    Authors: , , - Journal of Cell Science 2016 cited by 991

  7. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Priya S. Hibshman, Amber M. Amparo, Connor J. Hennessey, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jens Brodbeck, Lorenzo Tomassoni, Basil Bakir, Nicholas D. Socci, Laura E. Herring, Natalie K. Barker, Junning Wang, James M. Cleary, Brian M. Wolpin, John A. Chabot, Michael D. Kluger, Gulam A. Manji, Kenneth Y. Tsai, Miroslav Sekulic, Stephen M. Lagana, Andrea Califano, Elsa Quintana, Zhengping Wang, Jacqueline A.M. Smith, Matthew Holderfield, David Wildes, Scott W. Lowe, Michael A. Badgley, Andrew J. Aguirre, Robert H. Vonderheide, Ben Z. Stanger, Timour Baslan, Channing J. Der, Mallika Singh, Kenneth P. Olive - Nature 2024 cited by 175

  8. KRAS: feeding pancreatic cancer proliferation

    Authors: , , , - Trends in Biochemical Sciences 2014 cited by 684

  9. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Research 2022 cited by 160

  10. The Ras superfamily at a glance

    Authors: , , - Journal of Cell Science 2005 cited by 1,531

  11. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2019 cited by 226

  12. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

    Authors: , , , - Nature reviews. Cancer 2010 cited by 816

  13. Ras history

    Authors: , - Small GTPases 2010 cited by 713

  14. Drugging RAS: Know the enemy

    Authors: , - Science 2017 cited by 395

  15. KRAS inhibitors: resistance drivers and combinatorial strategies

    Authors: , , , - Trends in cancer 2024 cited by 157

  16. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2018 cited by 192

  17. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew V. Biankin, Kenneth R. Shroyer, Brian M. Wolpin, Andrew J. Aguirre, Andrea Ventura, Barry S. Taylor, Channing J. Der, Daniel Domínguez, Daniel Kümmel, Andrea Oeckinghaus, Scott W. Lowe, Robert K. Bradley, Omar Abdel‐Wahab, Steven D. Leach - Cancer Cell 2020 cited by 158

  18. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

    Authors: , , , , , , , , , , , , , , - Cancer Research 2023 cited by 80

  19. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors

    Authors: , , - Nature Reviews Molecular Cell Biology 2005 cited by 1,722

  20. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2019 cited by 173

  21. Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kian‐Huat Lim, Andrea Wang‐Gillam, Krister Wennerberg, Adrienne D. Cox, Channing J. Der - Science 2024 cited by 108

  22. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2015 cited by 275

  23. Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science 2024 cited by 81

  24. Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts

    Authors: , , , , , , , , - Science 1997 cited by 1,593